title: Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
abstract: In a double blind randomised multicentre study the effect of intravenous clodronate plus hydration was compared with placebo plus hydration in the treatment of hypercalcaemia in breast cancer patients with bone metastases. The patients were treated either with hydration plus clodronate 300 mg/day or hydration plus placebo, up to 7 days or until serum ionised calcium was below 1.4 mmol/l. 25 patients received clodronate and 19 placebo. A significant difference in favour of clodronate was observed in the time to reach normocalcaemia (P = 0.004) and in the number of patients achieving normocalcaemia (P = 0.0003). 17 patients of 21 evaluable patients on clodronate achieved normocalcaemia compared with 4 of 19 patients on placebo. The only adverse event clearly associated with clodronate was symptomatic hypocalcaemia in 1 patient. Thus, clodronate seems to be a safe and highly efficacious drug for the treatment of hypercalcaemia in breast cancer patients.
authors.affiliation: Department of Oncology, Danderyd Hospital, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Rotstein
authors.forename: U
authors.initials: U
authors.lastname: Glas
authors.forename: M
authors.initials: M
authors.lastname: Eriksson
authors.forename: P
authors.initials: P
authors.lastname: Pfeiffer
authors.forename: J
authors.initials: J
authors.lastname: Hansen
authors.forename: J
authors.initials: J
authors.lastname: Söderqvist
authors.forename: U
authors.initials: U
authors.lastname: Bandmann
authors.forename: S
authors.initials: S
authors.lastname: Strid
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001798:Blood Proteins / Q000378:metabolism; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary* / Q000652:urine; D001943:Breast Neoplasms / Q000097:blood* / Q000652:urine; D002118:Calcium / Q000097:blood / Q000652:urine; D004002:Clodronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005440:Fluid Therapy; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D006996:Hypocalcemia / Q000139:chemically induced; D007262:Infusions, Intravenous; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies
chemical_list: D001798:Blood Proteins; D010919:Placebos; D004002:Clodronic Acid; D006909:Hydroxyproline; D002118:Calcium